Iclusig (Ponatinib)

Save over 50% on brand name Iclusig from Euope.

Non-english packaging is often present for European medicines- English label and English insert included. Plan in advance - allow us 7 days to ship this brand name medicine.

According to the European Medicines Agency, brand name Iclusig originating from Europe is manufactured at the following site(s): Incyte Biosciences Distribution B.V. Paasheuvelweg 25 1105 BP Amsterdam NetherlandsTjoapack Netherlands B.V. Nieuwe Donk 9 4879 AC Etten-Leur Netherlands

Information about Iclusig (Ponatinib)

Iclusig (Ponatinib) is a targeted therapy used in the treatment of certain types of leukemia. It is an oral tyrosine kinase inhibitor that specifically targets the BCR-ABL fusion protein, which is commonly associated with chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL).

Product Highlights

• Designed for patients with specific genetic mutations, including T315I mutation, making it effective for resistant cases.
• Chronic Myeloid Leukemia (CML) in chronic, accelerated, or blast phases.
• Acute Lymphoblastic Leukemia (ALL) with the Philadelphia chromosome.
• Patients with resistance or intolerance to other tyrosine kinase inhibitors.

Key Ingredient

• Ponatinib

Key Benefits

• High response rates in patients with resistant mutations.
• Focused action on BCR-ABL and its mutations.
• Oral administration simplifies the treatment regimen.

Direction of Use

• Follow the physician's prescription closely. Initial doses often start at 45 mg once daily, but adjustments may be made based on response and tolerability.
• Regular blood tests are necessary to monitor for effectiveness and potential side effects.

Safety Concerns

• Common side effects include hypertension, rash, headache, and myelosuppression (decreased bone marrow function).
• Risk of arterial occlusive events (heart attack, stroke) and severe liver toxicity.
• Patients should be monitored for cardiovascular health and liver function during treatment.

Avoid Iclusig (Ponatinib) If

• Known hypersensitivity to Ponatinib or any of its components.
• History of serious cardiovascular conditions may contraindicate use.
• Significant liver dysfunction or disease.
• Should be avoided because of the potential risks to the fetus or infant.